The capacity of VP22 chimeric proteins to spread from the primary transduced cell to surrounding cells could improve gene therapy approaches, especially in cancer therapy. However, there are conflicting data about VP22 -mediated intercellular trafficking in different studies. To assess the role of VP22 in gene therapy of hepatocellular carcinomas ( HCCs ) we constructed expression vectors for N -and C -terminal versions of VP22 -p53 fusion proteins and investigated the VP22 -mediated shuttle effect in hepatoma cells by cotransfection experiments. VP22 -mediated trafficking was not detectable in hepatoma cells in vitro by fluorescence microscopy, but reporter gene transactivation assays demonstrated intercellular trafficking of functional VP22 -p53 in vitro. For in vivo experiments, the recombinant adenoviruses Ad5CMVp53 and Ad5CMVp53 -VP22 were constructed. In contrast to the in vitro experiments intercellular trafficking of VP22 -p53 could be observed in subcutaneous tumors of hepatoma cells by fluorescence microscopy, indicating a stronger shuttle effect in solid tumors compared to cell culture experiments. Because spread of p53 -VP22 in liver tumors was correlated with enhanced apoptosis of hepatoma cells VP22 -mediated trafficking of potential therapeutic proteins may improve the results of gene therapy of HCCs.
H epatocellular carcinoma ( HCC ) is one of the main complications of liver cirrhosis and a serious health problem worldwide. The growth of HCCs is often restricted to the liver, and extrahepatic metastases occur at late stages of tumor progression. Surgical resection is usually considered as the treatment of choice for HCCs, but the majority of the patients are inoperable because of tumor extension and severe cirrhosis. 1, 2 HCCs less than 5 cm in diameter can be injected percutaneously with coagulating agents ( 95% ethanol, 50% acetic acid ) or can be treated by radiofrequency ablation. 3, 4 There are many established options to treat HCCs but generally, the clinical outcome of patients with HCCs remains poor. As a consequence, new methods for the effective treatment of liver tumors have to be developed.
Gene therapy with viral vectors such as adenoviruses may be an attractive tool to treat HCCs in the future. Actually, the main problem of tumor gene therapy is the low rate of tumor cell transduction in vivo by the available vectors. In addition, preclinical studies in animals demonstrated high liver toxicity after application of high -titer adenoviral vectors, which limits the applicability of gene therapy particularly in patients with liver cirrhosis. 5 -9 Several protein domains have been described that exhibit the ability to passage cell membranes in a receptorindependent fashion and could, therefore, be used for protein transduction in gene therapy approaches 10, 11 (reviewed in Ref. [ 12] ). It has been shown that the herpes simplex virus type I tegument protein VP22 is exported from the cytoplasm of an expressing cell into neighboring cells. This property is retained by VP22 fusion proteins 13 -15 serving a strategy to enhance the efficacy of cancer gene therapy and circumvent the problem of toxicity of high -titer vectors in patients with liver cirrhosis. The molecular mechanisms involved in VP22 -mediated intercellular transport are poorly understood, but distinct domains have been identified to exert binding and reorganization of cytoskeleton, intercellular transport, and nuclear targeting. 16 However, reports of VP22 -shuttle effect in different cell lines in vitro are conflicting, 17, 18 and there are only limited data about VP22 -mediated intercellular trafficking in vivo. 19, 20 To assess the role of VP22 in gene therapy of HCCs we investigated the VP22 -mediated intercellular transport of p53 /VP22 fusion proteins in hepatoma cells in vitro and in vivo. A functional reporter gene transactivation assay demonstrated intercellular trafficking of transcriptional active p53-VP22 in hepatoma cells in vitro. In contrast to the in vitro experiments, intercellular transport of p53 -VP22 could be observed in subcutaneous tumors of hepatoma cells by fluorescence microscopy, which was correlated with enhanced p53-mediated apoptosis. Our data suggest that the use of VP22 fusion proteins will be an attractive approach to enhance the efficacy of gene therapy of HCCs.
Materials and methods

Cell lines, plasmids
The human hepatoma cell line Hep3B and the human embryonal kidney cell line 293 were obtained from the American Type Culture Collection ( Rockville, MD ). The SV40 transformed renal fibroblast cell line COS -1 was friendly provided by Susanne Franz, DKFZ Heidelberg, Germany. The cells were maintained in growth medium ( Dulbecco's modified Eagle's medium + glutamax, Life Technologies, Paisley, UK ) supplemented with 10% heatinactivated fetal bovine serum (Life Technologies ), 100 U / mL penicillin, and 100 g /mL streptomycin ( Biochrom AG, Berlin, Germany ) at 378C in 5% CO 2 .
The expression vector for p53 wild -type pCp53 -SN3 was kindly provided by B Vogelstein ( Baltimore, MD ). For construction of prMin -RGC the 13xRGC fragment was excised from the plasmid pSK -45 -13 -2 -PyCAT (provided by B Vogelstein ) by digestion with HindIII / EcoRI followed by a Klenow fill-in and ligated with the Klenow -blunted KpnI site of pGL -2 Basic (Promega, Madison, WI ). For the downstream insertion of a CMV minimal promoter the oligonucleotides 5 0 -GCGAGCTCGTACGGTGGGAGGGCTA TATAAGCAGACCTCGTTTAGTGAACCGTCAGATCGC CTGGAGACGAAGCTTCCG -3 0 ( antisense ) and 5 0 -CGG AAGCTT-CGTCTCCAGGCGATCTGACGGTTCACTAA ACGAGG -TCTGCTTATATAGCCCTCCCACCGTACGA GCTCGC -3 0 ( sense ) were annealed, digested with HindIII / SacI and cloned into the respective sites of pGL -2 Basic.
The plasmid pCMV / p53-VP22 for expression of a Cterminal VP22 -fusion of p53 was generated by PCR cloning using the oligonucleotides 5 0 -AAAAGCTTGCCGCCATG-GAG GAGCAGCCGCAGTCAGATCCTAGCG -3 0 (sense ) and 5 0 -TTGCGGCCGCCGTCTGA GTCAGGCCCTTCT-GTCTTG -3 0 (antisense ) and the p53-cDNA of pCp53 -SN3 as template. The resulting PCR fragment was HindIII / NotI digested and subcloned into pVP22 /myc -His2 (Invitrogen, Paisley, UK ). To construct the expression vector for the Nterminal fusion protein the p53 -cDNA fragment was isolated by HindIII (Klenow )/ NotI digest from the plasmid pCMV /p53 -VP22 and subcloned in frame into the KpnI ( Klenow ) / NotI sites of pVP22 /myc -His. The cDNA of the fusion proteins VP22 -p53 and p53 -VP22 were controlled by DNA sequencing and protein expression from pCMV / p53 -VP22, and pCMV /VP22 -p53 was confirmed by p53-immunohistochemistry after transfection in Hep3B cells.
GFP -screening, b -galactosidase histochemistry, terminal dUTP nick -end labeling and p53 -immunofluorescence in cell culture and tumor sections -Galactosidase expression was monitored by plating Hep3B cells in 60-mm dishes at 3Â10 5 cells / well. Twenty -four hours before transfection 300 ng CMV -Gal were cotransfected with 50 ng pC53-SN3, pCMV / p53-VP22, or pCMV /VP22 -p53. Twenty -four hours after transfection cells were washed twice with PBS and fixed with 100% EtOH. Cells were then stained overnight with 1 mg /mL X -Gal solution containing 5 mM K 3 FeCN 6 , 5 mM K 4 FeCN 6 , and 2 mM MgCl 2 . For monitoring of GFP fluorescence 2.5 g of a GFP -expressing vector ( pBCHGHBpc ) were cotransfected with expression plasmids for p53. GFP fluorescence was detected using an Olympus BX 60 microscope with U -MWIG filter ( 520-550 nm; Hamburg, Germany ). P53 /VP22 immunofluorescence was performed using either anti -p53 -AB2 (Oncogene Science, Schwalbach, Germany ) in a dilution of 1:250 or anti -His -tag ( Invitrogen ) in a dilution of 1:100. Secondary antibody was Cy3 -anti -mouse-IgG (Sigma, Deisenhofen, Germany ). p53/VP22 immunofluorescence was detected using a U -MNIB filter ( Olympus).
Tumor samples of the treated animals were embedded in O.C.T. compound ( Sakura, Zoeterwonde, Netherlands) and shock frozen in liquid nitrogen. The samples were stored at À 808C. Seven -micrometer sections were prepared and fixed in cacodylate buffer with 4% paraformaldehyde for 30 minutes at room temperature. GFP fluorescence was detected using an Olympus BX 60 microscope with U -MWIG filter ( 520 -550 nm ). For p53 immunofluorescence the sections were treated with 100 l anti -p53-AB7 ( Calbiochem, Bad Soden, Germany ) diluted 1:500 in phosphate -buffered saline. Secondary antibody (Cy3 -conjugated donkey antigoat, Dianova, Hamburg, Germany ) was used in a dilution of 1:200. Both incubations were performed for 20 minutes. p53 immunofluorescence was detected using U -MNIB ( 470-490 nm ) filter ( Olympus). Terminal dUTP nick -end labeling was performed according to the manufacturer's protocol ( in situ cell detection kit, Roche, Mannheim, Germany ). After washing twice with phosphate -buffered saline, the sections underwent a proteinase K incubation to digest virally expressed EGFP protein to avoid interference with the green fluorescence of the TUNEL reagent.
Adenoviral vector construction and preparation
Recombinant adenoviruses were constructed using the AdEasy system (Quantum, Montreal, Canada ) that has been described previously. 21 The viral vectors expressing wildtype p53 (AdGFP /p53 ) and the p53 -VP22 fusion protein ( AdGFP /p53 -VP22 ) were generated by inserting either the p53 cDNA containing HindIII / XbaI fragment derived from pCp53 -SN3 or the respective fragment from pCMV /p53 -VP22 into the shuttle vector AdTrack -CMV. In the resulting AdTrack constructs, the transgene expression is driven by a CMV promoter. They further contain a GFP expression cassette for convenient monitoring of infected cells. The infective adenoviral vectors were generated by homologous recombination of the shuttle vectors with AdEasy-1 in E. coli BJ5183 to obtain AdGFP /p53wt and AdGFP /p53 -VP22.
For preparation of high -titer viral stocks, 2Â10 8 293 packaging cells at 90% confluency were infected at a multiplicity of infection (MOI) of 5-10. The infected cells were maintained for 3 -5 days until a strong cytopathic effect could be observed and about 50% cells were detached. The cells were then collected by centrifugation and viral particles were released by four cycles of freezing in liquid nitrogen and rapid thawing at 378C. For further purification the virus preparation was subjected twice to CsCl density gradient centrifugation. CsCl banding and determination of infectivity by viral plaquing were performed according to standard protocols. Virus preparations were stored at À 208C in 25% glycerol, 10 mM Tris /HCl, pH 7.4, and 1 mM MgCl 2 .
Cancer Gene Therapy Hep3B cells were implanted subcutaneously in nude mice. A tumor nodule of 2Â2 cm was observed 6 weeks after inoculation of tumor cells. Tumor-bearing nude mice were treated with direct infiltration of AdGFPp53 or AdGFP/ p53 -VP22 at a dose of 5Â10 9 pfu in a total volume of 1 mL phosphate -buffered saline.
Luciferase assays
Hep3B cells ( 3Â10 5 ) were seeded in 60 -mm dishes 24 hours before transfection. The cells were transfected with 2.5 g prMin-RGC, 50 ng p53 expression vectors using either calcium phosphate precipitation method with an overnight incubation at 3% CO2 and 358C or LipofectAMINE 2 ( Gibco, Paisley, UK ), according to the manufacturers protocol. All proteins were expressed under the transcriptional control of the CMV immediate early promoter / enhancer. Total amount of transfected DNA was adjusted to 5 g /dish with pBluescript KS ( Stratagene, Amsterdam, Netherlands ). Whole -cell extracts were obtained 24 hours after transfection and measured for luciferase activity using a Berthold Lumat LB9501 ( Berthold, Bad Wildbad, Germany ) according to standard procedures. Luciferase activity was normalized by cotransfection of 0.5 g CMV-Gal.
Results
VP22 -mediated trafficking is strongly enhanced in solid hepatoma tumors compared to cell cultured hepatoma cells
To elicit properties of p53-VP22 for gene therapy of liver cancer we subcloned expression vectors for N -and Cterminal versions of VP22 -p53 fusion proteins, driven by the cytomegalovirus early promotor region. The shuttle function of VP22 was investigated in cell culture by cotransfection of EGFP-expression plasmids with expression vectors for VP22 -p53 proteins (N -and C -terminal ).
Because intensive VP22 -mediated intercellular trafficking has been described in COS -1 cells we used this cell line as a positive control for our in vitro experiments. EGFP expression was monitored by fluorescence microscopy. Expression of p53/VP22 fusion proteins and of the Cancer Gene Therapy VP22-mediated trafficking of therapeutic proteins L Zender et al original unfusioned VP22 protein was monitored by immunofluorescence staining. Because COS -1 cells harbor intact p53 alleles, we used a His -tag -antibody to investigate VP22 -mediated intercellular transport of p53-VP22 and VP22 -p53. Figure 1 shows that we could confirm VP22 -mediated intercellular trafficking in COS -1 cells, although the extent of spreading appears to be reduced by the fusioned p53 domain compared to the unfusioned VP22 protein.
We next investigated Hep3B hepatoma cells where the intrinsic p53 gene is deleted on both alleles. In contrast to COS -1 cells, in Hep3B hepatoma cells intercellular trafficking could only be demonstrated for unfusioned VP22, but not for p53 -VP22 or VP22 -p53 by immunofluorescence (Fig 2) .
To investigate whether VP22 -mediated intercellular spreading could be enhanced by viral infection we Figure 4 Schematic representation of a reporter gene transactivation assay to evaluate VP22 -mediated trafficking in vitro. Subconfluent grown Hep3B cells were cotransfected with 2.5 g prMin -RGC, 50 ng p53 expression vectors, and 300 ng pCMV -Gal using either calcium phosphate precipitation method ( A ) or LipofectAMINE 2 transfection method ( B ). Calcium phosphate transfection leads to a low transfection rate. If there is a VP22 -mediated shuttle effect, p53 -VP22 will predominantly be exported in neighboring cells without p53 -dependent reporter genes, resulting in a low quotient of p53 -VP22 luc activity / p53wt luc activity. LipofectAMIN 2 transfection reaches much higher transfection rates. A higher quotient of p53 -VP22 luc activity / p53wt luc activity in this assay would indicate that p53 -VP22 is predominantly transported in cells containing p53 -dependent reporter plasmids as a consequence of high transfection rate and would indirectly demonstrate the VP22 -mediated trafficking of p53 -VP22. were identical indicating that every p53 -overexpressing cell was transduced by adenovirus. However, in cells transduced with AdGFP /p53 -VP22 there was also an identical pattern in GFP fluorescence and p53 immunofluorescence indicating that no VP22 -mediated shuttle effect was detectable (Fig 3A ) . We next established Hep3B subcutaneous tumors in nude mice to investigate whether the three -dimensional architecture of a solid tumor would result in enhanced VP22 -mediated spreading compared to cell culture experiments. After needle injection of 5Â10 9 pfu of adenoviral vectors into subcutaneous Hep3B -tumor nodules the GFP -and p53-fluorescence patterns were nearly identical in the control experiments with AdGFP /p53wt, whereas a strong intercellular transport of p53 -VP22 could be observed with AdGFP/ p53-VP22 (Fig 3B ) . These results clearly demonstrate that cell culture experiments underestimate the capacity of VP22 -mediated intercellular Figure 5 Ratio of reporter gene transactivation by p53 versus p53 -VP22 is dependent on transfection efficacies indicating intercellular trafficking of transcriptional active p53 -VP22. Cotransfections were performed as described in Figure 4 . Cells were harvested 24 hours post transfection for measuring of luciferase activity or were stained with X -Gal solution. Calcium phosphate transfection resulted in a transfection rate of about 5%. Luciferase activity of p53 wild type was about 17 -fold higher than of p53 -VP22 under these conditions ( A ). Using LipofectAMINE 2 transfection, a transfection rate of about 40% positive cells was detectable resulting in a 7 -fold higher luciferase activity of p53 -VP22 ( B ). Figure 6 Enhanced apoptosis in Hep3B subcutaneous tumors is correlated with intercellular trafficking of p53 -VP22. Established Hep3B subcutaneous tumors were infected with 5Â10 9 pfu AdGFP, AdGFP / p53, or AdGFP / p53 -VP22 by direct infiltration of the tumor. Twenty -four hours after infection the tumors were harvested for preparation of cryosections. After proteinase K incubation to digest virally expressed EGFP protein, terminal dUTP nick -end labeling was performed using in situ cell death detection kit ( Roche ).
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Assessment of intercellular spreading of p53-VP22 in hepatoma cells in vitro by reporter gene transactivation assays
To evaluate whether the missing shuttle effect in cultured Hep3B cells was due to limited sensitivity of immunofluorescence microscopy we developed a reporter gene-based assay to investigate intercellular trafficking. Figure 4 elucidates the experimental setting. We performed cotransfection experiments of a luciferase -linked p53-dependent promoter construct together with expression plasmids for p53wt, p53-VP22, and -Gal. Blue spots represent primary transfected cells. In case that there is a shuttle function of p53 -VP22 the expressed protein will be exported to neighboring cells harboring no reporter gene (Fig 4A ) , which would result in low luciferase activity and in a low quotient of p53 -VP22 luc activity /p53wt luc activity. If there is a higher primary transfection rate p53 -VP22 would be transported also in primary transduced cells harboring a reporter gene ( Fig 4B ) , which should lead to relatively higher luciferase activity of p53-VP22 and to a higher quotient of p53 -VP22 luc activity / p53wt luc activity compared to the assay with lower transfection efficacy.
Cotransfected -Gal expression plasmid allows the detection of primary transfected cells. Using calcium phosphate transfection efficacies were about 5% whereas LipofectAMINE 2 transfection resulted in rates of about 40-50% ( Fig 5 ) . Figure 5 , A and B reports the different luciferase activities in comparing a primary low with a primary high transfection rate. Performing the reporter gene experiment with low transfection efficacy leads to 17 -fold higher luciferase activity for p53wt compared to p53-VP22 indicating VP22 -mediated trafficking of p53 -VP22 in untransfected cells that did not contain p53-dependent reporter plasmids. In contrast the same experiment with a transfection rate of about 40-50% resulted in 7 -fold higher transactivation activity of p53-VP22 compared to p53wt demonstrating that the low transactivation capacity of p53-VP22 in the former assay was an artifact due to VP22 -mediated intercellular trafficking. Actually, p53-VP22 revealed more transactivation activity than p53wt when it is predominantly transported in cells expressing reported plasmids. As a consequence of these results, in contrast to the experiments with immunofluorescence microscopy, we could indirectly demonstrate intercellular trafficking of p53 -VP22 in Hep3B in vitro with reporter gene transactivation assays.
VP22 -mediated spreading of p53 in hepatoma cells in vivo correlates with enhanced apoptosis
To investigate the property of intercellularly spread p53-VP22 to induce apoptosis we performed TUNEL assays of HCCs. Established tumors of Hep3B cells were infected with AdGFP, AdGFP /p53, or AdGFP/ p53-VP22. Tumors were harvested 24 hours post infection to perform terminal dUTP nick -end labeling. Figure 6A demonstrates that infection of the tumors with AdGFP resulted in a slight but distinct rate of apoptosis. Transduction of the tumors with AdpGFP /p53wt resulted in heterogeneous patterns of apoptotic cells (Fig 6B ) . However, adenoviral delivery of p53 -VP22 into the tumor nodules lead to a significant higher rate of apoptosis throughout the tumor nodule, indicating that VP22 -mediated spreading of p53 -VP22 is correlated with enhanced rate of p53-mediated apoptosis in HCCs.
Discussion
The tumor suppressor gene p53 is mutated or deleted in approximately 50% of human malignancies. Tumor suppressor gene therapy with the p53 protein has been proposed as a possible therapy for malignancies lacking active p53. HCC is one the leading causes of cancer mortality worldwide. As there is no efficient treatment for HCC available at the moment, there is the need for development of alternative therapies for the treatment of liver tumors. Several studies demonstrated that reintroduction of active p53 in hepatoma cells, which are characterized by inactivation of p53, can kill these cells very effectively. 22, 23 A major problem for p53 gene therapy approaches is the need of high primary transduction rates of the tumor. Systemic application of adenoviral vectors coding for p53 leads to predominant transduction of normal liver tissue but only low transduction rates of the tumor. 24 To improve the transduction of tumor cells versus normal hepatocytes some studies used regional hepatic artery infusion instead of systemic application. 23 However, until now there is no administration route available that provides transduction rates that are sufficient to reach effective regression of hepatic tumors by p53-replacement gene therapy.
VP22 mediates intercellular transport of proteins fused to its N -or C -terminus providing an approach to deliver functional chimeric proteins into a high percentage of target cells. The fusion proteins VP22 -p53 and p53-VP22 have been described to spread from primary expressing cells in vitro to neighboring cells and induce apoptosis in a p53 -negative osteosarcoma cell line. 13 Thus, VP22 -mediated intercellular distribution of the p53 protein could resurrect p53 cancer gene therapy circumventing the problem of low transduction rates of the tumor.
To assess the potential role of VP22 in gene therapy of liver tumors we evaluated the VP22 shuttle effect in hepatoma cells in vitro and in vivo. Using immunofluorescence staining no VP22 -mediated intercellular transport was evident in Hep3B hepatoma cells in vitro, in contrast to the transformed renal fibroblast cell line COS -1. As a missing shuttle effect in cell culture experiments could also be the result of limited sensitivity of immunofluorescence. 25 We used a highly sensitive reporter gene transcription assay that should allow the detection of low amounts of shuttled protein. The N -terminal transactivation domain of p53 is strongly suppressed in VP22 -p53 resulting in nearly complete loss of p53-transactivation capacity (data not shown). p53 wild -type protein requires posttranslational modification within the carboxy -terminal negative regulatory domain to activate DNA binding and transcription of the target gene. 26, 27 As a consequence of the suppressive effect on the inhibitory C -terminal domain of p53 by VP22, p53-VP22 exposes improved transcriptional activities compared to p53 wild type in cell culture experiments with high transfection rates. However, in cell culture experiments with low transfection rates p53 -VP22 is exported predominantly in neighboring cells that harbor no p53 -dependent reporter gene, resulting in lower luciferase activity than p53 wild type. Through this reporter gene transactivation assay we were able to reveal VP22 -mediated intercellular trafficking in hepatoma cells in vitro that was not detectable by immunofluorescence.
In contrast to the cell culture experiments we were able to demonstrate a strong widespread VP22 -mediated intercellular trafficking in subcutaneously grown Hep3B tumors using the same immunofluorescence staining as in vitro. These results suggest that VP22 -mediated spreading is strongly enhanced in solid tumors compared to cultured cells. Different explanations for this phenomenon are conceivable. The three -dimensional structure of the tumor where one cell is surrounded by lots of other cells could promote VP22 -mediated trafficking. Furthermore, cell culture conditions may result in altered expression of proteins in hepatoma cells that are necessary for sufficient intercellular transport of p53 -VP22. Taken together the strong intercellular transport of p53-VP22 in solid tumors could mean a real improvement of p53 gene therapy approaches if the shuttled protein is functionally active. To address this question we used adenoviral -mediated gene transfer and investigated the properties of p53-VP22 and p53 wild type to induce apoptosis in subcutaneous liver tumors in nude mice. Using TUNEL test for detection of apoptotic cells, we found out that there was a higher rate of apoptotic cells in p53 -VP22 -treated tumors compared to tumors treated with p53 wild type.
The higher apoptotic index could be explained by intercellular transport of p53 -VP22, but it is also likely that the enhanced transcriptional activity of p53-VP22 could contribute to higher rate of apoptosis. In summary, our data suggest that VP22 -mediated shuttle of the p53 tumor suppressor protein could mean a real improvement of the therapy of liver malignancies.
